Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,258
datasets available to search
ShareScore release 0.9.0
Dataset results
1,258 results for “neuroblastoma”
Transcriptome analysis identifies molecular effectors of unconjugated bilirubin in human neuroblastoma SH-SY5Y cells: 1h
GEO Series GSE16766. Homo sapiens. 6 samples. Type: Expression profiling by array.
Targeting SWI/SNF ATPases reduces cell invasiveness and plasticity in core transcription factors-addicted neuroblastoma [ChIP-seq]
GEO Series GSE240589. Homo sapiens. 30 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Childhood Cancer Data Initiative (CCDI): Clonal Evolution During Metastatic Spread in High-Risk Neuroblastoma
The goal of this study is to deliver a detailed characterization of the patterns of disease dissemination at diagnosis, during progression and in response to therapy in high-risk neuroblastoma. Longitudinal and spatially distinct tumors were collected from patients. Clinical data includes diagnosis and treatment information. Biospecimen data includes whole genome sequencing (WGS) and whole transcriptome sequencing (WTS).
Childhood Cancer Data Initiative (CCDI): Pediatric In Vivo Testing Program - Neuroblastoma
The goal of NCI's Pediatric In Vivo Testing Consortium (PIVOT) is to advance the development of effective treatments for pediatric cancers through preclinical in vivo testing of novel therapeutic agents. To design impactful experiments that can be rapidly translated to the clinic, PIVOT investigators require comprehensive genomic characterization of the patient-derived xenograft (PDX) models used across the consortium. This robust experimental design enhances collaboration with industry partners by providing proof-of-concept data for drugs in development. As part of this effort, neuroblastoma PDX models are being molecularly characterized to identify promising therapeutic candidates. The molecular profiling includes whole exome sequencing (WES), RNA-seq, MethylEPIC array, CytoSNP array, and DNA fingerprinting for quality control. Additionally, demographic and clinical data (e.g., diagnosis, disease site, disease status) are shared. These characterized PDX models, matched with patient tumors, guide model selection for preclinical drug testing.
Kids First: Neuroblastoma
Children with disseminated neuroblastoma have a very high risk of treatment failure and death despite receiving intensified chemotherapy, radiation therapy and immunotherapy. The long-term goal of our research program is to ultimately improve neuroblastoma cure rates by first comprehensively defining the genetic basis of the disease. The central hypothesis to be tested here is that neuroblastoma arises largely due to the epistatic interaction of common and rare heritable DNA variation. Here we will perform a comprehensive whole genome sequencing of 563 quartets of neuroblastoma patient germline and diagnostic tumor DNAs and germline DNAs from both parents. The case series was recently collected through a Children's Oncology Group epidemiology clinical trial and is robustly annotated with complete demographic (age, sex, race, ethnicity), clinical (e.g. age at diagnosis, stage, risk group), epidemiologic (parental dietary and exposure questionnaire) and biological (e.g. tumor MYCN status and multiple other tumor genomic measures) co-variates. Subjects were consented for genetic research and DNA is immediately available for shipment for sequencing. We propose Illumina-based whole genome sequencing in the 593 "trio" germline samples (Aim 1; due to missing parent: 487 full neuroblastoma triads, 106 child-single parent dyads = 1673 whole genome sequences) and matched diagnostic tumor DNA (Aim 2; N=366) at 30x sequencing depth (N=2039 whole genome sequences). Also in Aim 2 we will perform whole exome (100x) and RNA sequencing on the 366 tumor DNA and 228 tumor RNA samples from this cohort. Finally, we propose a pilot study of structural variation using long-range sequencing in 10 non-overlapping tumor samples chosen based on potentially relevant chromosomal alterations discovered with conventional NGS. Thus, a total of 2277 individual samples and 2655 sequences will be generated. We will use our established analytic pipeline that is currently being used to study the germline genomes of all cases sequenced through the NCI supported Therapeutically Applicable Research to Generate Effective Treatments program. We plan a three-stage analytic approach, first focusing on classic de novo and inherited Mendelian damaging alterations. We will next integrate our extensive epigenomic data from human neuroblastoma cell lines and genome-wide association study data (N=5,703 neuroblastoma cases to date) to guide a comprehensive assessment of noncoding variants that influence tumor initiation with a recently established analytic pipeline. Finally, we will utilize the tumor DNA analyses to inform relevance via somatic gain or loss of function effects at the sequence and/or copy number levels.
Integrated bioinformatic and wet-lab approach to identify potential oncogenic networks in neuroblastoma and other tumors
GEO Series GSE16254. Homo sapiens. 163 samples. Type: Expression profiling by array.
Transcriptional analysis of Rest/Nrsf silencing in N18 neuroblastoma cell line
GEO Series GSE14326. Mus musculus. 6 samples. Type: Expression profiling by array.
Copper chelation redirects neutrophil function to enhance anti-GD2 antibody therapy in neuroblastoma [GeoMx]
GEO Series GSE281844. Mus musculus. 100 samples. Type: Other.
Gene expression profiling of human neuroblastoma cell line LA1-55n expressing shGFP or shRNA to glycine decarboxylase (GLDC)
GEO Series GSE129807. Homo sapiens. 6 samples. Type: Expression profiling by array.
DNA methylation changes at CpG and non-CpG sites are associated with development and clinical behavior in neuroblastoma [gene expression]
GEO Series GSE54720. Homo sapiens. 23 samples. Type: Expression profiling by array.
Expression data of human neuroblastoma tissue samples
GEO Series GSE16237. Homo sapiens. 51 samples. Type: Expression profiling by array.
Demonstration of ClinGenNBL v2: A Model-based Application for the Management of Data associated with Neuroblastoma
Open the record for dataset details and reuse information.
Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma
ClinicalTrials.gov study NCT06858501. IPD Sharing: Not stated. Countries: 0. Publications: 0.
131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
ClinicalTrials.gov study NCT01370330. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma
ClinicalTrials.gov study NCT07067346. IPD Sharing: NO. Countries: 1. Publications: 0.
Gene Expression in Predicting Outcome in Samples From Patients With High-Risk Neuroblastoma
ClinicalTrials.gov study NCT01520233. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Biomarkers in Young Patients With Neuroblastoma
ClinicalTrials.gov study NCT01169376. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.
ClinicalTrials.gov study NCT06047535. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma
ClinicalTrials.gov study NCT00730444. IPD Sharing: Not stated. Countries: 1. Publications: 0.
CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study
ClinicalTrials.gov study NCT00013806. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.